Current medicinal chemistry · 2026
Design, Synthesis, and Pharmacological Characterization of Substituted Quinoxalines as NOP Receptor Ligands.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kyle Donald J, Tsuno Naoki, Tafesse Laykea, Ueno Tatsuhiko, Yamada Toru, Shinohara Shunji, Hasebe Nobuyoshi, Iso Yasuyoshi, Shan Shen, Bhargava Shweta, Crumley Gregg, Tanaka Nobuyuki, Yemawaki Kenji, Fuchino Kouki, Knappenberger Terri, Hummel Michele, Whiteside Garth T, Taoda Yoshiyuki, Kato Akira
Аннотация
INTRODUCTION: The goal of this work was the discovery of moderate-efficacy, selective, partial agonists of the nociceptin/orphanin-FQ peptide (NOP) receptor.
METHODS: A novel collection of quinoxaline-containing molecules was designed, synthesized, and assayed against NOP and mu-opioid receptors in vitro to establish the relationship between structural modification and pharmacological activity. The lead molecule identified was further assessed in vivo to determine brain penetration, analgesic effects in rodent models of pain, and motor deficits.
RESULTS: This SAR approach revealed that the phenyl portion of the quinoxaline is highly sensitive to modification. The unsubstituted phenyl produced a potent partial agonist (5), whereas most other substitutions created presumed antagonists or molecules that bind poorly to the receptor. Compound 5 was analgesic in rodent models of inflammatory and neuropathic pain at doses that did not produce motor deficits.
DISCUSSION: The goal of this work was achieved in discovering moderate-efficacy, selective, partial agonists of the NOP receptor. The analgesic efficacy of compound 5 is consistent with the effects of other NOP agonists in animal pain models. The partial agonist nature of 5 likely imparts a wider preclinical therapeutic index compared to full agonists.
CONCLUSION: The discovery of sunobinop (compound 5), a NOP partial agonist highly selective for NOP in vitro, was significant. Compound 5 produced antihyperalgesic efficacy in rodents and has progressed to clinical trials.
METHODS: A novel collection of quinoxaline-containing molecules was designed, synthesized, and assayed against NOP and mu-opioid receptors in vitro to establish the relationship between structural modification and pharmacological activity. The lead molecule identified was further assessed in vivo to determine brain penetration, analgesic effects in rodent models of pain, and motor deficits.
RESULTS: This SAR approach revealed that the phenyl portion of the quinoxaline is highly sensitive to modification. The unsubstituted phenyl produced a potent partial agonist (5), whereas most other substitutions created presumed antagonists or molecules that bind poorly to the receptor. Compound 5 was analgesic in rodent models of inflammatory and neuropathic pain at doses that did not produce motor deficits.
DISCUSSION: The goal of this work was achieved in discovering moderate-efficacy, selective, partial agonists of the NOP receptor. The analgesic efficacy of compound 5 is consistent with the effects of other NOP agonists in animal pain models. The partial agonist nature of 5 likely imparts a wider preclinical therapeutic index compared to full agonists.
CONCLUSION: The discovery of sunobinop (compound 5), a NOP partial agonist highly selective for NOP in vitro, was significant. Compound 5 produced antihyperalgesic efficacy in rodents and has progressed to clinical trials.